A few of the new articles are describing ASPS in a number of unusual sites:
1. Alveolar Soft-part Sarcoma of the Urinary Bladder With Urethral Recurrence: A Unique Case With Emphasis on Differential Diagnoses and Diagnostic Utility of an Immunohistochemical Panel Including TFE3.
American Journal of Surgical Pathology. 30(10):1322-1325, October 2006
http://www.ajsp.com/pt/re/ajsp/abstract ... 45!8091!-1
They report a unique case of ASPS presenting in the bladder with subsequent urethral recurrence in a 25-year-old woman.
2. Alveolar soft part sarcoma in brain with cardiac metastasis A case report.
International Journal of Cardiology , online, Letter to the Editor:
http://www.ncbi.nlm.nih.gov/entrez/quer ... med_docsum
From this abstract: "The use of modern treatment modalities, such as combination of surgery, and radiotherapy, may significantly prolong the survival time in many patients. Because of the long-term period with symptomatic brain tumors in this disease, the patients should be treated even in the presence of multiple metastases in other organs."
This is an important issue as some of our patients were not treated when disease was found metastatic at the presentation or progressed.
3. Alveolar soft-part sarcoma of the retroperitoneum.
International Journal of Urology, Volume 13, Number 10, October 2006, pp. 1355-1357(3)
http://www.ncbi.nlm.nih.gov/entrez/quer ... med_DocSum
Computed tomography showed a tumor (17 × 11 × 10 cm) in the left retroperitoneal space.
ASPS in an unusual sites - heart, bladder, retroperitoneum
New research, clinical trial outcomes, etc.
Return to “Medical Publications”
Jump to
- Welcome to CureASPS.org!
- ↳ Guest Book
- ↳ Forum Issues and Suggestions
- News and Updates
- ↳ Personal Stories and Updates
- ↳ Success Stories
- ↳ Rest In Peace
- ↳ Anonymous Patient Updates
- ↳ Chinese group news
- ↳ Medical Publications
- ↳ Other Publications
- ↳ Sarcoma Meetings and Conferences
- ASPS Clinical Trials
- ↳ Other Clinical Trials
- ↳ COMPLETED - ARQ 197 Clinical Trial
- ↳ COMPLETED - Dana Farber Vaccine Clinical Trial (GVAX)
- ↳ Dasatinib
- ↳ Alisertib
- ↳ Cediranib
- ↳ Anlotinib
- ↳ Immune checkpoint inhibitors (ICI)
- ↳ Axitinib and Pembrolizumab (Keytruda) in Miami, US
- ↳ TECENTRIQ (atezolizumab) by Genentech
- ↳ Pfizer's PF-06801591
- ↳ Durvalumab+Tremelimumab at MDACC
- Symptoms and Diagnostics
- ↳ Symptoms
- ↳ Scan Types and Follow-Up
- ↳ Molecular Studies
- ↳ Pathology results
- Primary Tumor Treatment
- ↳ Resection
- ↳ Treatment of Non-Resectable Primary Tumor
- ↳ Radiation
- Systemic Treatment
- ↳ TKI
- ↳ Sutent (sunitinib)
- ↳ Pazopanib
- ↳ Сabozantinib (Cometriq)
- ↳ Sorafenib
- ↳ Chemotherapy
- ↳ Metronomic chemotherapy
- ↳ Temozolomide (Temodar)
- ↳ Side effects of systemic treatments
- ↳ Interferon alpha
- ↳ Immune checkpoint inhibitors ICI (PD-1 and PD-L1 targeting drugs)
- ↳ Keytruda
- ↳ Opdivo
- ↳ TECENTRIQ (atezolizumab)
- ↳ Toxicity, problems and potentiation strategies
- ↳ Treatment response criteria and evaluation/scanning problems/rare cases
- ↳ treatment discontinuation/re-treatment
- Metastatic Disease Treatment
- ↳ Local treatment modalities
- ↳ cryoablation
- ↳ Side effects/complications of the local ablations
- ↳ Radiosurgery
- ↳ Microwave ablation
- ↳ High intensity focused ultrasound (HIFU)
- ↳ Lung Metastases
- ↳ Laser assisted surgery
- ↳ Brain Metastases
- ↳ Bone Metastases
- ↳ Other Metastases
- ↳ Abdominal Metastases
- ↳ Liver metastases
- ↳ Heart Metastases
- ↳ Spinal metastases
- ↳ Adrenal metastases
- ↳ Pancreatic metastases
- Living with ASPS
- ↳ Insurance Coverage
- ↳ Second opinion from a sarcoma center
- ↳ Finanical assistance
- ↳ Diet and lifestyle
- ↳ Related studies
- ↳ Pain management
- ↳ Travel assistance